We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00987727
First Posted: October 1, 2009
Last Update Posted: September 21, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Allergan
  Purpose
This study will evaluate the safety and efficacy of OPTIVE® MD for ocular surface integrity in symptomatic dry eye condition in absence of obvious eye-lid inflammation.

Condition Intervention Phase
Dry Eye Syndromes Keratoconjunctivitis Sicca Drug: carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD) Drug: sodium hyaluronate 0.18% (VISMED® Multi) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye

Resource links provided by NLM:


Further study details as provided by Allergan:

Primary Outcome Measures:
  • Change From Baseline in Global Ocular Staining Score at Day 35 [ Time Frame: Baseline, Day 35 ]
    Change from baseline in global ocular staining score (range from 0-15) at Day 35. The global ocular staining score is the sum of three different staining severities, each with a score of 0-5 on a 6-point scale, where 0 is no staining (best) and 5 is diffuse staining (worst).


Secondary Outcome Measures:
  • Change From Baseline in Ocular Surface Disease Index (OSDI) Questionnaire Score at Day 35 [ Time Frame: Baseline, Day 35 ]
    Change from baseline in Ocular Surface Disease Index (OSDI) questionnaire score at Day 35. The OSDI questionnaire consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions is assessed using a 5-point scale (where 0=none of the time and 4=all of the time). The score is converted to a 0-100 point score where 0 is no symptoms and 100 is most symptoms.


Enrollment: 82
Study Start Date: November 2009
Study Completion Date: September 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
carboxymethylcellulose 0.5% and glycerin 0.9% (OPTIVE® MD)
Drug: carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)
One drop in each eye three to six times daily, as needed
Other Name: OPTIVE® MD
Active Comparator: 2
sodium hyaluronate 0.18% (VISMED® Multi)
Drug: sodium hyaluronate 0.18% (VISMED® Multi)
One drop in each eye three to six times daily, as needed
Other Name: VISMED® Multi

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have been using artificial tears for at least 3 months prior to study inclusion
  • Have been using preservative free artificial tears at least three times daily (TIB) for at least 2 weeks immediately prior to study inclusion
  • Having moderate to severe symptoms suggestive of dry eye

Exclusion Criteria:

  • Current enrollment in an investigational drug or device study or participation in such a study within 3 months prior to entry into this study
  • Moderate to severe blepharitis
  • History or active signs of ocular trauma, ocular infection, or ocular inflammation within the last 3 months
  • History or active signs of ocular allergic disease or ocular herpes within the last year
  • History or active signs of severe or serious ocular conditions such as inflammatory corneal ulcers, recurrent erosions, and uveitis at any time.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00987727


Locations
France
Paris, France
Sponsors and Collaborators
Allergan
Investigators
Study Director: Medical Director Allergan
  More Information

Responsible Party: Vice President Medical Affairs, Allergan, Inc.
ClinicalTrials.gov Identifier: NCT00987727     History of Changes
Other Study ID Numbers: MAF-AGN-OPH-DE-011
First Submitted: September 29, 2009
First Posted: October 1, 2009
Results First Submitted: August 17, 2011
Results First Posted: September 21, 2011
Last Update Posted: September 21, 2011
Last Verified: August 2011

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Eye Diseases
Keratitis
Corneal Diseases
Lacrimal Apparatus Diseases
Glycerol
Hyaluronic Acid
Carboxymethylcellulose Sodium
Cryoprotective Agents
Protective Agents
Physiological Effects of Drugs
Adjuvants, Immunologic
Immunologic Factors
Viscosupplements
Laxatives
Gastrointestinal Agents